1. Home
  2. TCI vs MRSN Comparison

TCI vs MRSN Comparison

Compare TCI & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCI
  • MRSN
  • Stock Information
  • Founded
  • TCI 1983
  • MRSN 2001
  • Country
  • TCI United States
  • MRSN United States
  • Employees
  • TCI N/A
  • MRSN N/A
  • Industry
  • TCI Real Estate
  • MRSN Biotechnology: Pharmaceutical Preparations
  • Sector
  • TCI Finance
  • MRSN Health Care
  • Exchange
  • TCI Nasdaq
  • MRSN Nasdaq
  • Market Cap
  • TCI 240.5M
  • MRSN 252.0M
  • IPO Year
  • TCI N/A
  • MRSN 2017
  • Fundamental
  • Price
  • TCI $29.51
  • MRSN $1.86
  • Analyst Decision
  • TCI
  • MRSN Buy
  • Analyst Count
  • TCI 0
  • MRSN 6
  • Target Price
  • TCI N/A
  • MRSN $6.00
  • AVG Volume (30 Days)
  • TCI 4.5K
  • MRSN 1.1M
  • Earning Date
  • TCI 11-07-2024
  • MRSN 11-13-2024
  • Dividend Yield
  • TCI N/A
  • MRSN N/A
  • EPS Growth
  • TCI N/A
  • MRSN N/A
  • EPS
  • TCI 0.37
  • MRSN N/A
  • Revenue
  • TCI $49,821,000.00
  • MRSN $34,837,000.00
  • Revenue This Year
  • TCI N/A
  • MRSN N/A
  • Revenue Next Year
  • TCI N/A
  • MRSN N/A
  • P/E Ratio
  • TCI $80.90
  • MRSN N/A
  • Revenue Growth
  • TCI 4.46
  • MRSN N/A
  • 52 Week Low
  • TCI $26.29
  • MRSN $1.22
  • 52 Week High
  • TCI $43.40
  • MRSN $6.28
  • Technical
  • Relative Strength Index (RSI)
  • TCI 58.03
  • MRSN 42.16
  • Support Level
  • TCI $27.82
  • MRSN $1.93
  • Resistance Level
  • TCI $30.95
  • MRSN $2.81
  • Average True Range (ATR)
  • TCI 0.94
  • MRSN 0.24
  • MACD
  • TCI 0.04
  • MRSN -0.05
  • Stochastic Oscillator
  • TCI 57.43
  • MRSN 7.79

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Share on Social Networks: